Creesevita Subcutaneous Injection 20mg, featuring burosumab (genetical recombination), is a human monoclonal antibody medication manufactured by Kyowa Kirin. It is indicated for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), provided as a 20mg 1mL 1 bottle with YJ code 3999452A2020.
Creesevita Subcutaneous Injection 20mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →